Washington State Institute for Public Policy
Prev
Next
December 2016
The 2015 Washington State Legislature directed WSIPP to review existing literature and begin a four-year study to evaluate outcomes regarding the cost-effectiveness of FDA-approved long-acting injectable medications, focusing on the benefits to persons in prison when they are released into the community.

We review the research evidence on the effectiveness of these medications in reducing substance abuse and recidivism rates. Where possible, we calculate whether the benefits of administering long-acting injectable medications outweigh the costs.
Download: Report
Related:
Search WSIPP reports


Filter By Topic -
Benefit-cost analysis
Children’s services
Criminal justice
Adult corrections

Juvenile justice

Employment/Welfare
General government
Health care
Higher education
Inventories
Mental health
Pre-K-12 education
Prevention
Public health
Substance abuse
Transportation

Filter By Author -
Madeline Barch
Julia Cramer
Adam Darnell
Elizabeth Drake
Danielle Fumia
Rebecca Goodvin
Joshua Grice
Lijian He
Michael Hirsch
Chasya Hoagland
Stephanie Lee
Matt Lemon
Marna Miller
Catherine Nicolai
Eva Westley
(show all authors)

Filter By Date
From:  
To:  
BOARD
STAFF
CONTACT
 
110 FIFTH AVENUE SE, SUITE 214
P O BOX 40999
OLYMPIA, WA 98504
 
360.664.9800
institute@wsipp.wa.gov